Duopharma trailblazes M’sia’s biosimilar industry

Beginning with this issue, The Petri Dish will be featuring local life science-biotech companies that are riding the high waves in the business world. We kick off this monthly take with Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma who shared his thoughts with company Chief Operating Officer, WAN AMIR JEFFERY WAN ABDUL MAJID. Leonard is aspiring to make his company the leading Big Pharma in Asean.

Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma...

CCM Duopharma Biotech Berhad (Duopharma), one of Malaysia’s leading pharmaceutical company, was established in 1979. Since then, it has grown to become one of Malaysia’s pioneers in the biosimilar industry – besides already being a leading manufacturer of generic medicines and branded consumer healthcare products in the country and in Asean.

A biosimilar product is also known as a “follow-on biologic” or “subsequent entry biologic” which is almost an identical copy of an original product which has been manufactured by a different company.

Following a demerger from CCM Berhad in December 2017, Duopharma attained a significant milestone in just 2018 alone, with its quest for new drugs and treatments.